Diabetes, obesity & metabolism

Semaglutide and Tirzepatide linked to alcohol-related outcomes in type 2 diabetes

Updated

Abstract

Adults with Type 2 diabetes initiating semaglutide, tirzepatide, or sodium-glucose cotransporter-2 inhibitors may have differing risks of developing alcohol use disorder.

  • The study aims to assess the incidence of alcohol use disorder among adults with Type 2 diabetes.
  • Three treatment options are being compared: semaglutide, tirzepatide, and sodium-glucose cotransporter-2 inhibitors.
  • Understanding these risks could provide insights into the safety profiles of these medications for individuals with Type 2 diabetes.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free